Optimizing combination treatment in the management of type 2 diabetes
Giuseppe Derosa, Salvadeo SibillaDepartment of Internal Medicine and Therapeutics University of Pavia, Pavia, ItalyAbstract: Obtaining the suggested glycemic control is the most important achievement in order to prevent cardiovascular complications in patients with type 2 diabetes. Monotherapy often...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2007-11-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | https://www.dovepress.com/optimizing-combination-treatment-in-the-management-of-type-2-diabetes-peer-reviewed-article-VHRM |
| _version_ | 1811226841021677568 |
|---|---|
| author | Giuseppe Derosa Salvadeo Sibilla |
| author_facet | Giuseppe Derosa Salvadeo Sibilla |
| author_sort | Giuseppe Derosa |
| collection | DOAJ |
| description | Giuseppe Derosa, Salvadeo SibillaDepartment of Internal Medicine and Therapeutics University of Pavia, Pavia, ItalyAbstract: Obtaining the suggested glycemic control is the most important achievement in order to prevent cardiovascular complications in patients with type 2 diabetes. Monotherapy often fails after a period of treatment, so that multiple drugs are needed to achieve effective glycemic control. A number of oral glucose lowering drugs is now available such as metformin, sulfonylureas, non-sulfonylureas secretagogues (metiglinides derivatives), alpha-glucosidases inhibitors, and the newest agent: thiazolidinediones (TZD). The possible associations of oral glucose lowering drugs for optimal treatment of type 2 diabetes are briefly reviewed. In particular, the effects of different classes of drugs on cardiovascular risk factors (and particular hypertension and dyslipidemia) and well recognized cardiovascular disease markers in type 2 diabetes are analyzed: in this context TZD appear the more innovative drugs and have been shown to play a key role in the management of hypertension, dyslipidemia, inflammation and endothelial disfunction in diabetic patients. The possible adverse effects derived from the association of different drug classes are also considered.Keywords: type 2 diabetes, combination therapy, cardiovascular risk factors |
| first_indexed | 2024-04-12T09:31:39Z |
| format | Article |
| id | doaj.art-bfa0ddc21a2f453492660b72f5aae544 |
| institution | Directory Open Access Journal |
| issn | 1178-2048 |
| language | English |
| last_indexed | 2024-04-12T09:31:39Z |
| publishDate | 2007-11-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Vascular Health and Risk Management |
| spelling | doaj.art-bfa0ddc21a2f453492660b72f5aae5442022-12-22T03:38:21ZengDove Medical PressVascular Health and Risk Management1178-20482007-11-01Volume 36656711533Optimizing combination treatment in the management of type 2 diabetesGiuseppe DerosaSalvadeo SibillaGiuseppe Derosa, Salvadeo SibillaDepartment of Internal Medicine and Therapeutics University of Pavia, Pavia, ItalyAbstract: Obtaining the suggested glycemic control is the most important achievement in order to prevent cardiovascular complications in patients with type 2 diabetes. Monotherapy often fails after a period of treatment, so that multiple drugs are needed to achieve effective glycemic control. A number of oral glucose lowering drugs is now available such as metformin, sulfonylureas, non-sulfonylureas secretagogues (metiglinides derivatives), alpha-glucosidases inhibitors, and the newest agent: thiazolidinediones (TZD). The possible associations of oral glucose lowering drugs for optimal treatment of type 2 diabetes are briefly reviewed. In particular, the effects of different classes of drugs on cardiovascular risk factors (and particular hypertension and dyslipidemia) and well recognized cardiovascular disease markers in type 2 diabetes are analyzed: in this context TZD appear the more innovative drugs and have been shown to play a key role in the management of hypertension, dyslipidemia, inflammation and endothelial disfunction in diabetic patients. The possible adverse effects derived from the association of different drug classes are also considered.Keywords: type 2 diabetes, combination therapy, cardiovascular risk factorshttps://www.dovepress.com/optimizing-combination-treatment-in-the-management-of-type-2-diabetes-peer-reviewed-article-VHRM |
| spellingShingle | Giuseppe Derosa Salvadeo Sibilla Optimizing combination treatment in the management of type 2 diabetes Vascular Health and Risk Management |
| title | Optimizing combination treatment in the management of type 2 diabetes |
| title_full | Optimizing combination treatment in the management of type 2 diabetes |
| title_fullStr | Optimizing combination treatment in the management of type 2 diabetes |
| title_full_unstemmed | Optimizing combination treatment in the management of type 2 diabetes |
| title_short | Optimizing combination treatment in the management of type 2 diabetes |
| title_sort | optimizing combination treatment in the management of type 2 diabetes |
| url | https://www.dovepress.com/optimizing-combination-treatment-in-the-management-of-type-2-diabetes-peer-reviewed-article-VHRM |
| work_keys_str_mv | AT giuseppederosa optimizingcombinationtreatmentinthemanagementoftype2diabetes AT salvadeosibilla optimizingcombinationtreatmentinthemanagementoftype2diabetes |